VO-Ohpic trihydrate is a effective PTEN inhibitor (antagonist) with IC50 of 46±10 nM.

Physicochemical Properties

Molecular Formula	2[C6H5NO3].HO2V.3[H2O]
Molecular Weight	416.21168
Exact Mass	414.011
Elemental Analysis	C, 34.80; H, 3.65; N, 6.76; O, 42.49; V, 12.30
CAS #	476310-60-8
Related CAS #	VO-OHPic;675848-25-6
PubChem CID	66577002
Appearance	Light green to green solid powder
Hydrogen Bond Donor Count	9
Hydrogen Bond Acceptor Count	13
Rotatable Bond Count	0
Heavy Atom Count	26
Complexity	384
Defined Atom Stereocenter Count	0
InChi Key	HCJXRYXYWPOIGP-UHFFFAOYSA-K
InChi Code	InChI=1S/2C6H5NO3.4H2O.O.V/c2*8-4-2-1-3-7-5(4)6(9)10;;;;;;/h2*1-3,8H,(H,9,10);4*1H2;;/q;;;;;;;+3/p-3
Chemical Name	Hydroxy(oxo)vanadium 3-hydroxypyridine-2-carboxylic acid complex trihydrate
Synonyms	VO OHpic; VO-OHpic; VOOHpic
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	PTEN (IC50 = 35 nM)
ln Vitro	Since VO-OHpic is a sterically demanding compound with two OHpic and one oxo ligand, it makes sense that steric hindrance from the bound substrate would impact the inhibitor's subsequent binding. At low nanomolar doses (IC50, 46±10 nM), VO-OHpic substantially reduced PTEN activity, which is consistent with the efficacy found in a PIP3-based assay earlier (IC50, 35±2 nM). It was found that the inhibitory constants Kic and Kiu were, respectively, 27±6 and 45±11 nM[1]. A promising selective and effective PTEN inhibitor is VO-OHpic. The most effective PTEN lipid phosphatase activity inhibitor is VO-OHpic (IC50=35 nM)[2].
ln Vivo	Mice's PTEN was suppressed by an intraperitoneal injection of VO-OHpic (10 μg/kg) 30 minutes before to ischemia, followed by exposure to ischemia for 30 minutes and reperfusion for 120 minutes. Triphenyltetrazolium chloride (TTC) was used to measure the size of the myocardial infarct at the conclusion of the experiment. In mice treated with VO, the size of the myocardial infarct was considerably smaller (25±6% vs. 56±5%, n=7, P<0.01). Between the two groups, there was no difference in the risk area (46±3% vs. 57±3%, n=7, P>0.05) [3].
References	[1]. Characterisation of the PTEN inhibitor VO-OHpic. J Chem Biol. 2010 Oct;3(4):157-63. [2]. A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol. 2006 Dec 15;1(12):780-90. [3]. PTEN inhibitors cause a negative inotropic and chronotropic effect in mice. Eur J Pharmacol. 2011 Jan 10;650(1):298-302.

Solubility Data

Solubility (In Vitro)

DMSO: ~72 mg/mL (~173.4 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (6.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.02 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: 2% DMSO+40% PEG 300+2% Tween 80+ddH2O: 14mg/mL  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.4026 mL	12.0132 mL	24.0263 mL
	5 mM	0.4805 mL	2.4026 mL	4.8053 mL
	10 mM	0.2403 mL	1.2013 mL	2.4026 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.